THAR Form 3: Director James Liddy Reports 50,000-Share Option Grant
Rhea-AI Filing Summary
James Gordon Liddy filed an Initial Statement on Form 3 reporting his beneficial ownership in Tharimmune, Inc. (THAR). The filing, tied to an event dated 06/11/2025, shows a stock option granting the right to purchase 50,000 shares of common stock at an exercise price of $1.33 per share. The reporting person is identified as a Director. The explanatory note states that 25,000 options vested on the date of grant and the remaining 25,000 vest on 08/04/2026. The form is signed by the reporting person on 08/22/2025. The ownership is reported as direct.
Positive
- None.
Negative
- None.
Insights
TL;DR: Director received 50,000 stock options at $1.33, half vested immediately; disclosure is routine and not materially dilutive for most investors.
The grant gives the director economic exposure linked to common stock performance. With an exercise price of $1.33 and 25,000 shares vested immediately, the award aligns management and shareholder interests. Based solely on the filing, there is no information on total outstanding shares, so potential dilution or payoff cannot be quantified. This disclosure is standard Section 16 reporting for insider equity grants.
TL;DR: Routine insider grant disclosed promptly; vesting split signals retention intent but contains no governance concerns on its face.
The filing identifies the reporting person as a director and shows a retention/compensation element via a two-step vesting schedule (25,000 vested at grant, 25,000 vesting 08/04/2026). Such schedules are common to promote continued service. The form provides required transparency under Section 16 but includes no additional governance details like board approvals or related-party considerations.